Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California. Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. The Company maintains a discovery research program focused on peptide and protein therapeutics.

XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of multiple myeloma (MM) and hepatitis C. The Company’s lead compound is Recombinant Erythropoietin (rHuEPO), a known compound that it is developing for the prolongation of MM patients' survival and improvement of their quality of life. MM is a severe and incurable malignant hematological cancer of plasma cells. XTL’s second program is the Diversity Oriented Synthesis program (DOS), which is focused on the development of pre-clinical hepatitis C small molecule inhibitors, which the Company had out-licensed to Presidio Pharmaceuticals, Inc. (Presidio), which is a private specialty pharmaceutical company on March 20, 2008.

Dragon Pharmaceutical is looking to build a pharmaceutical empire in the PRC. Headquartered in Canada, the company has production facilities within mainland China that manufacture active pharmaceutical ingredients (APIs), intermediates, and finished formulations. It sells its bulk APIs and intermediates, which are used in antibiotic formulations, both in China and internationally (mainly in India). Its finished products (sold only in China) are primarily injectable cephalosporin antibiotics. In 2007 Dragon Pharmaceutical divested its biotech division in order to focus on its core antibiotic operations. CEO Yanlin Han holds nearly half of the company's stock and is seeking to buy the balance.

FLAVORx, Inc. company offers a medical flavoring system which makes medicine more palatable for children, (and some adults). The company doesn't neglect our furry friends either, as the product is also available to veterinarians. Using 42 flavors to sweeten some 600 human and nearly 400 animal medications, FLAVORx sells its products to about 35,000 pharmacies located in the US, as well as in Australia, the Bahamas, Canada, and New Zealand. CEO Kenny Kramm started the company out of the need to hide the bitter taste of his daughter's cerebral palsy medicine.

Botanical Laboratories was founded in 1988 and is led by CEO Jim Thornton, a long-time venture capital investor in the consumer health care sector. Botanical Laboratories, Inc. (BLI) is your garden-variety nutritional supplement maker. It manufactures its own branded nutritional supplements and also offers private label manufacturing of nutritional supplements and homeopathic remedies. BLI's consumer products include dietary supplements distributed under its Wellesse brand and sold at retail food and drug stores, such as CVS and Costco. From capsule to carton, its contract manufacturing division offers customers turnkey production and packaging, development, quality control, and testing services nationwide.

U.S. Genomics, Inc. company has developed the GeneEngine, a DNA sequencer that mimics natural cell division, rapidly reading and copying DNA. It is developing the technology to quickly detect and identify infectious pathogens and biomarkers for biodefense and diagnostic use. Its products can detect and quantify molecules of DNA, RNA, and proteins without amplification. Backed by private equity investors and biomedical firms including Becton Dickinson, U.S. Genomics has netted contracts with the Department of Homeland Security. Northrup Gruman is the company's bio-security development partner.

Nanospectra Biosciences, Inc. was founded in 2002 and is based in Houston, Texas. Nanospectra Biosciences, Inc., a medical device company, engages in developing and commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors. The company provides AuroLase Therapy, a medical device that is applicable to the ablation of various solid tumors. It also offers research-use-only nanoparticles with specific optical characteristics.

SCOLR Pharma, Inc. is a specialty pharmaceutical company, which through its Controlled Delivery Technology (CDT) platforms, develops prescription, over-the-counter (OTC) and nutritional products. The Company has developed multiple private-label controlled release nutritional products incorporating its CDT platforms that are sold by national retailers. The Company’s lead product candidate is a CDT-based controlled release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation. It completed the pivotal phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 milligram controlled release ibuprofen for the OTC market. In addition, the Company submitted its first abbreviated new drug application (ANDA) for its 12-hour pseudoephedrine product on August 5, 2008.

Allermed Laboratories, Inc. company was founded in 1971. Allermed Laboratories knows that in the case of allergies, a little bit of what caused the problem can be the solution. The company manufactures allergenic extracts, such as plant pollens, insects, fish and shellfish, and various foods, used to both diagnose and treat allergic conditions. The company is also developing additional skin tests for allergies, as well new tests to detect Leishmania parasite infections and exposure to the fungus Coccidioides immitis. Other products include empty test vials, vial trays, diluents, and extract mixing syringes. Outside of allergists' offices, the company provides environmental testing kits to detect mold contamination of buildings.

Laureate Pharma's protein purification and other production processes are pure poetry in motion. The contract manufacturing organization (CMO) develops, manufactures, and packages products used by pharmaceutical and biopharmaceutical companies to make drugs and diagnostics. The company's biopharmaceutical division specializes in making monoclonal antibodies and provides protein production and purification. Laureate also provides product formulation, aseptic filling, and bulk processing. It has partnerships with EMD Chemicals and GTC Biotherapeutics to provide products for clinical trials. Investment firm Safeguard Scientifics has sold its majority stake in Laureate Pharma to Saints Capital.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.